Crohn\u27s disease : enteral nutrition practices of registered dietitians in New Mexico by Horvath, Nicole Sara
University of New Mexico
UNM Digital Repository
Individual, Family, and Community Education
ETDs Education ETDs
1-30-2013
Crohn's disease : enteral nutrition practices of
registered dietitians in New Mexico
Nicole Sara Horvath
Follow this and additional works at: https://digitalrepository.unm.edu/educ_ifce_etds
This Thesis is brought to you for free and open access by the Education ETDs at UNM Digital Repository. It has been accepted for inclusion in
Individual, Family, and Community Education ETDs by an authorized administrator of UNM Digital Repository. For more information, please contact
disc@unm.edu.
Recommended Citation
Horvath, Nicole Sara. "Crohn's disease : enteral nutrition practices of registered dietitians in New Mexico." (2013).
https://digitalrepository.unm.edu/educ_ifce_etds/40
i 
 
Nicole Horvath          
Candidate 
 
 
Department of Individual, Family & Community Education   
Department 
 
 
 
This thesis is approved, and is acceptable in quality and form for 
publication: 
 
Approved by the Thesis Committee: 
 
 
Deborah Cohen                , Chairperson  
 
 
Elizabeth Yakes           
 
 
Jean Cerami            
 
 
 
 
 
 
 
 
 
 
ii 
 
 
 
 
 
 
CROHN’S DISEASE 
ENTERAL NUTRITION PRACTICES OF REGISTERED 
DIETITIANS IN NEW MEXICO  
 
 
BY 
 
 
NICOLE HORVATH, RD, LD 
BACHELOR OF SCIENCE IN NUTRITION/DIETETICS 
UNIVERSITY OF NEW MEXICO 
2006-2012 
 
 
 
 
 
THESIS 
 
Submitted in Partial Fulfillment of the  
Requirements for the Degree of 
 
Master of Science 
Nutrition 
 
The University of New Mexico 
Albuquerque, New Mexico 
 
December 2012 
iii 
 
DEDICATION  
I dedicate this paper to Robert Ackerman, a close friend of mine.  
Robert has lived with Crohn’s disease for most of his life.  Over the years, Robert 
has exposed me to the impact that Crohn’s disease can have on one’s life.  He continues 
to struggle with Crohn’s disease not knowing what each new day will bring.  As an 
individual with Crohn’s disease, he faces an uncertain future until advancements in 
Crohn’s disease research are made that can help improve the available medical treatments 
in healthcare or a cure is discovered for Crohn’s disease.  Robert Ackerman, thank you 
for demonstrating that “life isn’t about waiting for the storm to pass; it’s about learning to 
dance in the rain” (Unknown). 
 
iv 
 
ACKNOWLEDGEMENTS 
I sincerely acknowledge Deborah Cohen, my advisor and thesis chair, for her 
continued support, motivation, openness, availability and encouragement through my 
matriculation at the University of New Mexico.  She has provided me with a substantial 
foundation of knowledge in the field of Nutrition and Dietetics.  Her guidance, 
professionalism, kindness and devotion to helping others will remain with me as I 
continue my career in dietetics. 
I appreciate the efforts of my committee members in their endeavor to help me 
succeed academically and professionally.  I would like to thank my committee members, 
Elizabeth Yakes and Jean Cerami, for their continued support, specialized knowledge, 
and valuable recommendations pertaining to this study and assistance in my professional 
development. 
Lastly, I would like to thank my friends and family for their patience, optimism 
and encouragement! 
 
  
v 
 
CROHN’S DISEASE: ENTERAL NUTRITION PRACTICES OF  
REGISTERED DIETITIANS IN NEW MEXICO 
 
by 
 
Nicole S. Horvath, RD, LD 
 
B.S., Nutrition/Dietetics, University of New Mexico, 2010 
M.S., Nutrition, University of New Mexico, 2012 
 
ABSTRACT 
 
Objective: To identify which enteral nutrition (EN) formulations are currently 
recommended in the acute care setting by registered dietitians (RDs) in New Mexico for 
patients with active Crohn’s Disease (CD) and to compare these recommended 
formulations to the ASPEN and ESPEN guidelines. 
Methods: The link to an electronic survey was e-mailed to 109 potentially eligible RDs 
employed at acute care facilities in New Mexico during the spring of 2011.  E-mail 
addresses were obtained from the Commission on Dietetic Registration.  Descriptive 
statistics, Fisher’s exact, Pearson’s χ2 and Cramer’s V tests (SPSS; version 21) were used 
to analyze relationships between variables.  
Results: Twenty-three participants fit the inclusion criteria and completed the survey 
(42.6% response rate).  All eligible participants were 26 to 64 years of age, 82.6% were 
females, 91.3% were Caucasian, 56.5% worked at an urban location, 69.6% had been 
practicing dietetics for more than 15 years and 56.5% worked solely with adult patients.  
Seventy-four percent of RDs reported using semi-elemental and elemental EN 
formulations.  ASPEN (26%), ESPEN (22%) and AND NCM (22%) guidelines were the 
most commonly reported guidelines used by RDs.  RDs employed at a rural locations 
(26.1%) were more likely to report access challenges (p = .025).  Practicing dietetics for 
less than 15 years (34.8%) was statistically associated with the use of ESPEN guidelines 
(p = .016).  RDs that reported using ASPEN and ESPEN guidelines (40%) did not 
necessarily recommend polymeric EN formulations for patients with active CD (p = 
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.382).  RDs that reported using ASPEN guidelines (67%) were more likely to report using 
polymeric EN formulations (p = .025).   
Conclusion:  RDs employed at acute care facilities in New Mexico generally recommend 
semi-elemental and elemental EN formulations for patients with active CD, even though 
the ASPEN and ESPEN guidelines recommend the use of polymeric EN formulations.  
This study demonstrated that access issues, limited available research and physician 
resistance to the use of EN may be factors associated with decreased use of EN in 
patients with active CD.  Further research on the use of EN in patients with active CD 
should be conducted, so that evidence-based guidelines can be developed.  
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CHAPTER 1: INTRODUCTION 
Crohn’s disease (CD), also known as regional enteritis, is a disease that was first 
described by Dr. Burrill B. Crohn and his colleagues in a paper published in 1932 (1).  
CD is a type of inflammatory bowel disease (IBD) that can affect any part of the 
gastrointestinal (GI) tract.  The two major types of IBD are ulcerative colitis and CD.  CD 
can affect the entire thickness of the small intestinal wall and typically occurs in the 
ileum and the proximal large intestine (2).  Unlike CD, ulcerative colitis only involves the 
colon and does not affect all layers of the intestinal wall.  CD can skip portions of the 
intestines leaving healthy, unaffected portions in between patches of diseased intestine 
(3).  CD typically consists of two phases: active and remission (3).  CD is considered 
active when symptoms are present or a patient has a score of greater than 150 using the 
Crohn’s Disease Activity Index (CDAI) on a scale of 0 to 600 (4).  CD symptoms in 
adults can differ from those in the pediatric population.  CD symptoms in adults may 
include diarrhea, cramping, fever, abdominal pain, nausea, decreased appetite, weight 
loss, fatigue and rectal bleeding (5, 6).  In the pediatric population, delayed onset of 
puberty and poor linear growth, weight gain and bone mineralization may be the primary 
symptoms of CD (2, 7).  CD is an idiopathic and incurable chronic condition, but it can 
be managed with medications, surgery, nutrition support or a combination of these 
therapies.   
 
There are five types of CD that are classified according to the location in the GI tract 
where the disease occurs (5).  Granulomatous colitis only affects the large intestine, while 
gastroduodenal CD affects both the stomach and duodenum and Crohn’s ileitis affects the 
ileum.  The most common type of CD is ileocolitis and it affects the large intestine and 
ileum.  Lastly, jejunoileitis produces patches of inflammation in the jejunum.  CD can 
cause severe complications, with voluminous diarrhea and corrosion caused by excessive 
secretion of digestive enzymes leading to fluid and electrolyte imbalances and nutrient 
deficiencies and promotion of the development of fistulas and intestinal obstructions (5, 
8, 9, 10).  
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The prevalence and incidence of CD have been increasing in Western countries since the 
1970’s (11).  The prevalence of CD in the United States (US) is approximately 320 out of 
100,000 people (11).  CD is most frequently diagnosed between the ages of 15 and 30 
years, but it may be diagnosed at any age (2).  There is a slight predominance of the 
female gender being diagnosed with CD.  Caucasians, especially those of Eastern 
European Jewish descent appear to develop CD more often than other ethnicities (6).   
 
The etiology of CD is complex.  A combination of environmental, genetic and 
autoimmune factors is thought to contribute to the development of CD (12).  Cigarette 
smoking has been found to be a risk factor in the development of CD and may promote 
an exacerbation of CD (11).  On the other hand, being breastfed in infancy may reduce 
the risk of developing CD in adulthood (7).  It is theorized that a Westernized diet high in 
saturated fat and processed foods may have an influence in the development of CD due to 
the presence of pro-inflammatory substances in a Westernized diet (9, 13, 14).   
 
Nutritional therapy in addition to surgical, medical or pharmacological therapies is 
important in the treatment of active CD (3).  Nutritional therapies (Table 1) may include 
parenteral nutrition (PN), enteral nutrition (EN), medical nutrition therapy (MNT) or a 
combination of these therapies (15, 16, 17).  EN has been found to stimulate remission in 
approximately 53 to 84% of individuals with active CD when used exclusively or as an 
adjunct to corticosteroids (8, 18).  However, EN appears to be more effective in inducing 
and maintaining remission in pediatric patients than in adults with CD and is more 
commonly used in the pediatric population (19). 
Table 1: Types of Nutritional Therapies 
Nutritional Therapy Description 
Parenteral Nutrition (PN)  Nutrition is provided through an intravenous tube called a catheter 
that is directly inserted into the veins (17). 
Enteral Nutrition (EN)  Nutrition is provided through a feeding tube into the GI tract (17).   
Medical Nutrition Therapy 
(MNT) 
 Nutrition assessment, intervention, monitoring and evaluation 
provided by a registered dietitian (RD) to manage a specific disease 
state (e.g. IBD) through diet (20). 
Approximately 75% of hospitalized patients with active CD have unintentional weight 
loss (15, 17).  Unintentional weight loss, specifically more than 10% of total body weight 
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in a period less than 6 months in an underweight individual, may deplete nutritional 
reserves and put the individual at risk for malnutrition.  An individual with unintentional 
weight loss may greatly benefit from nutrition therapy, such as oral nutrition supplements 
or EN (15, 21).  Malnutrition may impair the functions of the GI, cardiac, pulmonary, 
renal and immune systems; hence hindering healing, increasing the risk of health 
complications and predisposing an individual to a decreased quality of life (QOL) and 
loss of independence (21).  EN support either as an adjunct to oral nutrition or as sole 
nutrition is the therapy of choice in malnourished patients with active CD (15).  If a 
patient requires exclusive EN and does not tolerate EN support for five days, it is 
recommended that PN be initiated (12).  However, bowel rest may not be necessary in 
most patients with CD because it does not seem to affect remission in CD (17).   
 
The mechanism by which EN induces a remission in some patients is unclear, but may be 
due to: 1) exclusion of pro-inflammatory dietary components present in oral diets, 2) 
changes in bacterial flora, 3) reduction of total fat, or 4) the addition of glutamine in EN 
formulas that may decrease wound healing time (3, 12).  EN is recommended for patients 
with active CD if they are intolerant to corticosteroids, refuse corticosteroids, are 
undernourished, as an adjunct to corticosteroids and in patients that have inflammatory 
stenosis of the intestine (15).   
 
There are three types of EN formulations: elemental, semi-elemental and polymeric 
formulations (Table 2).  Elemental EN formulations are believed to be less allergenic and 
the easiest to absorb with nutrients provided in forms that require minimal digestion prior 
to absorption: nitrogen in the form of amino acids, carbohydrate as monosaccharides and 
fats primarily from medium-chain triglycerides (MCT) (8, 17).  The limitation of 
elemental EN formulations is their decreased palatability and increased cost.  Semi-
elemental formulations contain nitrogen as partially hydrolyzed protein blends (peptides), 
glucose polymers (sucrose or maltodextrin) and fat mostly as MCTs.  Research is lacking 
in the effectiveness of semi-elemental formulations in inducing remission in patients with 
CD.  On the other hand, polymeric formulations are generally more palatable and less 
expensive.  Polymeric formulations contain nitrogen in the form of whole proteins, 
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carbohydrates as hydrolysates of starch and fat from oils mostly in the form of long-chain 
triglycerides (LCT) and may be more difficult to digest and absorb in a person with a 
damaged intestinal mucosa.   
Table 2: Breakdown of Macronutrient Content of the Types of EN Formulations 
Types of EN  Polymeric Formulation Semi-Elemental Formulation Elemental Formulation 
Protein Content  Intact proteins or peptides 
 Usually from cow’s milk or 
soybeans 
 Peptides or a combination of 
peptides and amino acids 
 Amino acids  
Fat Content  Polyunsaturated fatty acids from 
corn, safflower, sunflower or 
soybean oil or from animal fat 
 A proportion of medium-chain 
triglycerides is usually 
provided to improve fat 
absorption 
 Medium-chain triglycerides 
Carbohydrate 
Content 
 Maltodextrin and hydrolyzed 
cornstarch, glucose-derived 
saccharides or corn syrup 
 Carbohydrate complexity varies 
and is generally lactose-free 
(sucrose or maltodextrin) 
 Monosaccharides 
Advantages  Increased palatability 
 Decreased cost 
 Easier to digest  
 Easier to absorb 
 Easier to digest  
 Easier to absorb 
Disadvantages  Nutrients must be broken down 
prior to absorption   
 May not be tolerated by the 
patient 
 Increased cost  
 Decreased palatability 
 Decreased palatability 
 High osmotic load of simple 
sugars and amino acids 
 Increased cost  
 
Researchers have investigated the effectiveness of the different EN formulations in 
inducing remission in patients with active CD (22, 23).  Evidence suggests that patients 
receiving an exclusive diet of a polymeric EN formulation may have similar remission 
rates to those who receive their sole nutrition from an elemental EN formulation (22).  
Polymeric formulations are generally more palatable and less expensive than elemental 
formulations, so they are generally recommended for use as an oral supplement in 
patients with active CD (15, 22).   
 
Benefits of using EN as a therapy for CD include improved weight, improved QOL, 
promotion of intestinal mucosal healing, promotion of beneficial bacterial flora in the 
intestine, reduction of the exposure of the mucosa to antigens, improved absorption of 
nutrients and resolution of protein loss (3, 9).  Additionally, the use of EN is correlated 
with reduction in levels of pro-inflammatory cytokines (9).  Elemental EN formulations 
may be beneficial for patients with CD because it has been observed that there are 
reduced total bacteria per gram in patient’s feces receiving an elemental EN formulation 
compared to a polymeric formulation (14, 17).  Animal studies have demonstrated that 
animals raised in a germ-free environment do not develop intestinal disease, thus 
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suggesting that use of exclusive EN may prevent a CD exacerbation due to decreased 
antigen exposure (24).  Additionally, exclusive consumption of an elemental EN 
formulation may allow for bowel rest and some studies have found remission rates to be 
as high as 84% in patients consuming an exclusive diet of elemental EN (25).   
 
The European Society for Parenteral and Enteral Nutrition (ESPEN) published guidelines 
in 2006, which recommend EN for patients who are undernourished and in the active 
stage of CD (15).  Polymeric formulations are recommended as the first nutritional 
therapy of choice and if symptoms of intolerance (diarrhea, constipation, abdominal 
distention, abdominal pain, nausea or vomiting) develop, then elemental EN formulations 
should be utilized (15, 26).  The American Society for Parenteral and Enteral Nutrition 
(ASPEN) published guidelines that are similar to ESPEN guidelines with respect to the 
recommendations regarding the promotion of EN in patients who cannot consume 
adequate nutrition orally (15, 16).  Additionally, both ASPEN and ESPEN guidelines 
recommend polymeric EN formulations as the primary nutrition therapy of choice, as 
there appears to be no significant difference between the types of EN formulations in 
inducing remission (16). 
 
Hospitalization is not uncommon in individuals suffering with CD, especially those with 
severe exacerbations of their disease.  Utilizing MNT during active CD may improve 
clinical outcomes (27).  The risk of developing malnutrition during acute exacerbations 
increases due to frequent medical procedures, need for bowel rest, severe diarrhea, 
nutrient malabsorption and hospital acquired infections.  Malnutrition is associated with 
negative outcomes, such as decreased lean body mass, weight loss, poor wound healing 
and decreased immune function, which can increase hospital length of stay (13, 28).  
Improving the nutritional status of patients with CD is a major goal.  Consultation with a 
registered dietitian (RD) is associated with improved medical efficiency, decreased 
nutrition-related hospitalizations and improvement in nutritional management (29).  In 
general, it has been found that specialized nutrition support is cost-effective and may 
prevent infectious complications as well as decrease the patient’s duration of 
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hospitalization by 51% (27).  However, there is no published data on the role of the RD 
in the treatment of patients with active CD. 
 
RD intervention may play an important role in the MNT for a patient with active CD.  
The RD can use MNT for the prevention of malnutrition, improvement of nutritional 
status, and promotion of remission and gut healing in patients with active CD (30).  
 
To date, there are no published studies regarding whether RDs utilize current clinical 
nutrition recommendations (ASPEN or ESPEN) for the use of EN in patients with active 
CD or what, if any, guidelines they currently use in the acute care setting.  The purpose of 
this study was to compare the EN formulations that are currently recommended in the 
acute care setting by RDs in New Mexico who provide MNT for patients with active CD 
to the current ESPEN and ASPEN guidelines.  For this study, an acute care facility was 
considered to be an accredited health care facility in New Mexico that admits patients for 
overnight stays for medical treatment.  The hypothesis of this study was that RDs that 
work in acute care facilities in New Mexico follow the current clinical nutrition 
guidelines (ASPEN and ESPEN) and recommendations for EN support in patients with 
active CD. 
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CHAPTER 2: REVIEW OF THE RELATED LITERATURE 
The purpose of this literature review is to summarize the most recent published literature 
on the use of EN support both as an adjunct to an oral diet and as the sole nutritional 
therapy in the treatment of patients with active CD.  In addition, current EN guidelines 
for CD will be reviewed, as well as the role the RD plays in the MNT for patients with 
active CD.  There are multiple therapies available for CD with the goal of reducing 
inflammation and the symptoms associated with the disease as well as prolonging the 
periods of remission between active CD exacerbations (3).  Limited published research 
has focused on the use of EN support for either sole therapy or as an adjunct to surgical 
and pharmacological therapies.  This literature review will focus on the use of EN as a 
therapy in adult patients with active CD.  Pediatric studies will be discussed as well, due 
to the limited published research conducted on adult patients with CD.   
Benefits of EN Therapy in the Treatment of Active CD 
CD incidence in the US has increased in the twentieth century, which may be related to 
the increased intake of potentially pro-inflammatory substances (saturated fat, sugar and 
sodium) found in processed and fast food, which are commonly consumed in Western 
diets (9, 13, 14). Western diets also contain large amounts of dust and food additives, 
which may promote an immune response when consumed (14).  EN as a sole source of 
nutrition allows for the avoidance of substances in the Western diet that may be pro-
inflammatory, which could potentially cause an exacerbation of CD in those with an 
already damaged intestinal mucosa (3, 13).  Evidence suggests that EN therapy may 
promote remission in adults with active CD and that it should be utilized more frequently 
to prevent active CD and maintain remission in these individuals (30).  
 
Another theory behind the pathogenesis of CD is that some bacteria in our environment 
are transmitted to the gut (i.e. via food consumption) and may promote the inflammatory 
process that is observed in CD (19).  In CD, there is an increase in intestinal permeability 
due to abnormalities in the tight junctions found between enterocytes in the intestines 
(17).  This may allow for antigen-uptake and promotion of bacterial growth, which 
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encourages the inflammation observed in CD.  In patients with IBD, there are a larger 
number of bacteria in contact with the intestinal mucosa (12).  Interestingly, IBD lesions 
occur in segments with the highest concentrations of bacteria, which is in the ileo-cecal 
valve and the colon.  Surgery involving removal of this part of the GI tract for CD 
patients decreases the rate of relapse of CD (12).   One group of investigators found that a 
diet consisting of an exclusive elemental EN formulation may be beneficial for patients 
with CD because it was observed that there were reduced total bacteria per gram in 
patient’s feces who received an exclusive diet of an elemental EN formulation, hence EN 
may promote remission and decrease the inflammatory process observed in CD (3, 31).   
Evaluation of the use of EN Therapy as a Treatment for Patients with Active CD 
The effectiveness of utilizing diets consisting of polymeric, semi-elemental and elemental 
EN formulations to achieve and maintain remission in patients with active CD has been 
evaluated (22).  These formulations have many important differences including the 
macronutrient composition and cost.  Elemental and semi-elemental formulations can 
cost up to 400% more than standard polymeric formulations (8).  The premise behind the 
use of elemental EN formulations is that patients with CD, who have a damaged 
intestinal mucosa, have a reduced ability to secrete digestive enzymes for adequate 
absorption of nutrients and villous atrophy, which may reduce absorptive capacity. 
 
Semi-elemental and elemental EN formulations are more easily absorbed, less allergenic 
and better tolerated in malabsorptive states than polymeric formulations because they 
require minimal digestion prior to absorption (8, 14, 23).  Polymeric formulations provide 
nitrogen as a whole protein and are considered standard formulations.  Polymeric 
formulations are less expensive, more palatable and are generally recommended as the 
primary EN formulation of choice (15). 
The Role of EN in Inducing Remission During Active CD   
The use of EN in the pediatric population is the preferred therapy for active CD because 
corticosteroids may impair children’s linear growth (13).  An estimated 20 to 30% of 
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children under the age of 16 years taking corticosteroids for CD have an abnormally short 
stature later in life (13, 19).   
 
Day et al. (19) demonstrated the benefits of EN in inducing remission and improving 
nutritional status in pediatric patients with active CD.  This study consisted of 27 male 
children between the ages of three and 16 years with active CD who consumed an 
exclusive diet consisting of a standard polymeric EN formulation (varying amounts of 
Osmolite or Modulen IBD depending on weight gain) for 6 – 8 weeks.  Eighty-nine 
percent of the children completed the study by consuming an exclusive EN diet for 6 – 8 
weeks (n = 12 with longstanding CD and n = 12 with newly diagnosed CD).  Nineteen 
children consumed the EN orally (80%) without the need for insertion of a naso-gastric 
(NG) feeding tube.  Seventy-nine percent of the children who completed the study 
entered remission, which was based on the Pediatric CDAI (on a scale of 0 to 80), with a 
score of less than 15 indicative of remission.  Gradually, a normal diet was reintroduced 
during the 15.2-month follow-up.   Eleven patients elected to continue supplementary EN 
(300 – 2750 ml/day without other medical therapies in four participants and in addition to 
other medical therapies in seven children) in addition to their oral diet.  This study 
reported improved standard inflammatory markers (e.g. erythrocyte sedimentation rate 
[27.83 vs. 17.62 mm/h, < .04], C-reactive protein [29.19 vs. 5.38 mg/L, p < .002], 
albumin [31.14 vs. 35.43 g/L, p < .02] and platelets [407 vs. 331.5 x10
9
/L, p < 0.049]) in 
all patients that entered remission.  None of the children lost weight during this study; 
however, by eight weeks, the children with long-standing CD that achieved remission (n 
= 7, 58%) gained an average of 4.86 kg compared to 2.29 kg in the children who did not 
(n = 5, p < 0.05).  Also, the children with newly diagnosed CD who achieved remission 
(n = 12, 100%) gained an average of 4.7 kg compared to 0.75 kg in children that did not 
complete their course of exclusive EN (n = 3, p < .05).  Linear growth of up to 3 cm was 
documented in this study; however, there was no change in height Z scores over the 6 – 8 
week period.  A limitation of this study was that the range of 300 to 2750 ml daily of EN 
is a large range and would have resulted in a huge variance in the amount of calories and 
nutrients consumed from the EN formulations.  The results of this study show that a diet 
consisting exclusively of a polymeric EN formulation can induce remission during an 
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exacerbation of CD, improve nutrition status, prevent weight loss and result in an 
improvement of inflammatory markers in patients with active CD.   
 
Borelli et al. (23) evaluated the efficacy of exclusive EN therapy (no other treatment) to 
that of corticosteroid therapy as treatments for pediatric patients with active CD.  This 
prospective trial consisted of 37 children (ages four to 17 years of age) who were 
randomly assigned to consume an exclusive polymeric EN diet (n = 19) or were provided 
oral corticosteroids with an unrestricted diet (n = 18) over a ten-week period.  The 
investigators found that there was significant improvements of mucosal healing, which 
was measured via the Crohn’s Disease Endoscopy Index of Severity and a histological 
scoring system, in the children consuming polymeric EN compared to the children that 
received an unrestricted diet with corticosteroids (74% vs. 33% of patients that were on 
corticosteroids exclusively, p < 0.05).  Intestinal healing was assessed by an endoscopy 
and histology at baseline and at the end of the study.  Limitations of this study include the 
small sample size that may have led to a lack of generalizability, the study was not 
blinded and the subjects were provided different dosages of EN and corticosteroids 
depending on the requirement of each patient.  Borelli’s data support the use of a 
polymeric formulation in children with active CD because use of polymeric EN 
formulations lead to increased mucosal healing.  Lastly, the investigators of this study 
emphasized the need for dietary measures that can prolong remission and decrease the 
need for pharmacotherapy and surgical interventions in CD.  
 
In a randomized controlled trial (RCT) conducted by Mansfield et al. (32), subjects were 
randomly assigned to receive an exclusive diet of semi-elemental or elemental EN 
formulations via NG feeding tubes for 28 days.  The purpose of this study was to assess 
the effectiveness of elemental and semi-elemental formulations as sole nutritional 
therapies for adults with active CD.  This study included 44 participants (63% males and 
37% females).  Twenty-two participants were randomized to the elemental diet group and 
the other 22 participants were given the semi-elemental formulation.  All medical 
treatments, including corticosteroids that patients were receiving prior to the study, were 
gradually withdrawn during the first 12 days of the study.  All participants received the 
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EN via an NG feeding tube with no other oral intake.  The EN consisted of an exclusive 
semi-elemental (oligopeptide, as the protein source; Pepti-2000 LF liquid) or elemental 
(nitrogen in the form of amino acids; Elemental 028) EN diet.  Sixteen (36.4%) 
participants (semi-elemental group n = 8, elemental group n = 8) achieved remission, 
which was determined by a reduction of the patient’s CDAI score by 100 points or 40% 
of the baseline value, control of symptoms and withdrawal of all treatments the 
participant was receiving prior to the study.  EN feedings were discontinued in six 
(13.6%) subjects due to intolerance to the NG tube and 22 (50%) participants did not 
attain clinical remission (11 from each group).  The results of this study support the use 
of semi-elemental and elemental formulations to promote improvements in CD symptoms 
and reduction in intestinal inflammation.  A major limitation of this study is that the ages 
of the participants were not published.  This is a limitation because the human body 
functions differently depending on one’s age.  An additional limitation is that prior 
medical treatments were withdrawn during the study period (there was no washout 
period), which may have affected the study’s results; especially since this study was only 
conducted over a 28 day period.  However, the investigators concluded that elemental EN 
formulations are not necessarily more beneficial than semi-elemental formulations in the 
treatment of adult patients with active CD.  
 
EN support can be used to induce and maintain remission (17, 22).  EN promotes 
intestinal healing and improves the nutritional status of CD patients; therefore polymeric 
EN formulations as an adjunct to other therapies for active CD should be utilized due to 
their cost-effectiveness and increased palatability to encourage increased dietary 
compliance. 
Clinical Nutrition Guidelines for EN Support in Patients with Active CD 
ESPEN Clinical Nutrition Guidelines for CD 
The European Society for Enteral and Parenteral Nutrition (ESPEN) is a 
multidisciplinary society that is dedicated to the study of metabolic problems associated 
with diseases and their nutritional implications (15).  ESPEN aims to encourage the rapid 
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diffusion of knowledge in the field of clinical nutrition and metabolism.  The ESPEN 
guidelines published in 2006 state that corticosteroids are a more effective treatment 
therapy in adult patients with active CD and that EN as a sole therapy is “indicated 
mainly when treatment with corticosteroids is not feasible”, e.g. due to intolerance or 
refusal...“combined therapy (EN and drugs) is indicated in undernourished patients as 
well as in those with inflammatory stenosis of the intestine” (15).  Also, ESPEN 
encourages the use of polymeric EN formulations as the primary formula of choice in 
addition to oral intake (15).   
According to ESPEN, indications for EN in patients with active CD include the 
“prevention and treatment of undernutrition, improvement of growth and development in 
children and adolescents, improvements in quality of life, acute phase therapy, peri-
operative nutrition [which refers to the three phases of surgery: preoperative, 
intraoperative, and postoperative nutrition] and maintenance of remission in chronic 
active disease” (15).  Maintenance of remission in the case of persistent intestinal 
inflammation can be achieved by using oral nutritional supplements (EN and 
vitamin/mineral supplements).  EN and oral nutritional supplements are recommended in 
addition to normal food, to improve the nutritional status of the patient and to eliminate 
consequences of malnutrition and growth retardation (15).   
 
According to ESPEN, there are no significant differences between the effects “of free 
amino acid, peptide-based and whole protein formulae for tube feeding” in patients with 
active CD (15).  Therefore, free amino acid (elemental) or peptide-based (semi-
elemental) formulations are not recommended, unless the patient cannot tolerate the 
polymeric formulation (15).    
ASPEN Clinical Nutrition Guidelines for CD 
The American Society for Parenteral and Enteral Nutrition (ASPEN) is an 
interdisciplinary organization devoted to improving patient care by advancing the science 
and practice of clinical nutrition and metabolism (20).  In 2008, ASPEN published 
clinical practice guidelines for IBD (16).  The ASPEN guidelines emphasize that EN 
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should be used in adult CD patients that require specialized nutrition support, but 
specialized nutrition support and bowel rest should never be the primary therapies for 
CD.  This emphasizes the need to encourage intake by mouth prior to initiation of enteral 
intake (tube feedings) and to provide EN as an adjunct to other therapies (medical, 
surgical and pharmacological).  Similar to ESPEN guidelines, ASPEN guidelines support 
the use of polymeric EN formulations because EN “effectively reverses malnutrition” 
(20).  Additionally, both ASPEN and ESPEN guidelines state that PN should be a last 
resort for patients with IBD, unless they have fistula-associated CD.  However, ASPEN 
does not provide recommendations on how EN should be provided to individuals with 
active CD. 
AND Nutrition Care Manual Guidelines for CD 
The Academy of Nutrition and Dietetics (AND) publishes an online diet and professional 
practice manual, the Nutrition Care Manual (NCM), that provides evidence-based 
nutrition care information for various medical conditions (33).  The NCM describes MNT 
for patients with active CD due to the digestive issues associated with CD.  The NCM 
states that EN or PN “is used as a supportive mechanism when oral diet or vitamin 
supplementation cannot meet nutritional needs” (33).  Additionally, the guidelines state 
that “formula choice will depend on [the] functional status of the [GI] tract”; however, it 
does not provide detailed information on the use of EN to help promote remission and 
nutritional stability in patients with active CD (33).  
Current Practices of the RD in the Treatment of Patients with Active CD 
The RD is important in the care of patients with disorders of the GI tract (21, 31, 34).  
RDs are qualified to identify inadequate nutrient intakes in patients with IBD and to 
provide individualized nutrition advice, which “improves nutritional knowledge, 
nutritional intake and nutritional status in patients with intestinal failure” (35).  In 2006, 
the United Kingdom (UK) conducted their first national audit in the area of 
gastroenterology and found that there was an unacceptably low number of RDs working 
in gastroenterology, with only 37% of CD patients who have ever seen a RD (34).  It is 
important to utilize the RD to promote optimal nutritional status in patients with IBD, to 
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prevent malnutrition and improve QOL (36).  The RD is important in the treatment of 
patients with active CD; however RDs are underutilized in gastroenterology in general 
(34, 35).  Utilizing RDs is essential in providing optimal care for patients with active CD 
to improve their medical outcomes and nutritional status. 
 
Prince et al. (28) aimed to identify and explore nutritional issues of concern to patients 
with IBD and their opinions of the health services that they receive for these nutritional 
issues.  Seventy-two adults diagnosed with either CD (n = 47) or ulcerative colitis (n = 
25) participated in this survey.  Fifty-six percent were females, 56% were white and all 
were older than 18 years (mean age of 39 years).  The participants completed a 
questionnaire that was administered via a face-to-face interview at adult outpatient 
gastroenterology clinics at Guy’s and St. Thomas’ NHS Foundation Trust in the United 
Kingdom.  Forty-five percent of all respondents rated food and nutrition as ‘important’ or 
‘extremely important’ with respect to their disease.  Eighty-three percent of individuals 
with CD reported experiencing problems with food and nutrition with 94% reporting 
problems with body weight, specifically unintentional weight loss.  Lethargy was 
reported by 85% of all respondents as an issue and was often associated with iron 
deficiency or poor overall nutritional intake.  Half of all respondents reported that they 
had consulted with an RD as part of their treatment.  A limitation of this study is that the 
authors did not report whether those who were referred to an RD found it to be beneficial 
or had improved health outcomes.  Results of this study suggest that individuals with IBD 
have nutritional concerns and may avoid foods that they perceive to exacerbate their 
condition, which may put them at nutritional risk for malnutrition or other nutritional 
deficiencies.  The investigators suggested that there is a need for RDs to provide 
individualized nutritional assessment and counseling to individuals with IBD to treat 
those with malnutrition or at risk for developing malnutrition as a result of their disease.   
The Role of the RD in Medical Nutrition Therapy 
There is limited research on the role of the RD on patient care or outcomes in the acute 
care setting.  The following discussion reviews studies on the skills and standards of care 
provided by nutrition experts (e.g. nutritionists, RDs), prescriptive practices of RDs, and 
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the positive impact that RD involvement in healthcare can have on patient and clinical 
outcomes.   
 
Due to the limited research available on practices of RDs for their patients with active 
CD, a study on the practices of RDs, nutritionists and physicians in the care of PKU 
patients will be discussed.  In 2008, a group of investigators conducted a survey at a 
meeting of the European Nutritionist Expert Panel on phenylketonuria (PKU) with 
attendees from ten European centres with the aim of highlighting the key differences in 
dietary management among the centres and exploring possible reasons for the differences 
(37).  Each centre was represented by a single RD, nutritionist or physician who 
completed the survey in person at the PKU meeting.  The questionnaire consisted of a set 
of questions that collected information regarding the number of patients who visited each 
centre, management guidelines, training background of the nutrition expert, their roles 
and responsibilities, the individuals responsible for monitoring the patient’s diet, 
reimbursement for monetary cost of special diets or food products, challenges associated 
with disease management and policies on specific diets.  The results of this study indicate 
that all the European centres have different recommendations and practices regarding 
nutritional therapy for PKU.  A limitation of this study includes the various training and 
education levels of the respondents because RDs, nutritionist and physicians have 
unequal training, status and responsibilities throughout Europe.  Degree courses in 
dietetics are not standard and RDs and nutritionists may have different skill sets and 
competencies depending on their training.  It was reported that in some centres, the 
physician, not the RD, prescribes the diet and the RD may only be involved in the 
discussion and provision of dietary information.  As a result of this study, the 
investigators concluded that it would be beneficial to standardize the nutritional therapy 
for PKU patients in order to provide optimal medical care.  This study suggests that 
practices vary among RDs and nutritionists in Europe in the nutritional therapy of PKU.  
As in this study, due to the limited published literature on RD practices on patients with 
active CD, it is possible that practices of RDs vary for their patients with active CD.    
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Weil et al. (38) surveyed 1,500 clinical nutrition managers (CNMs), using an online 
survey website.  The CNMs were employed at an acute care hospital with more than 150 
beds that were registered with the American Hospital Association in 2005.  The purpose 
of the survey was to evaluate the barriers to nutritional practices and prescriptive 
authority in the hospital settings in America.  Three hundred fifty-one CNMs responded 
to the survey with a response rate of 23%.  Fifty-four percent of respondents reported that 
they had no prescriptive authority.  Thirty-six percent of respondents reported dependent 
prescriptive authority meaning that the RD had the authority to order diets, nutritional 
supplements, nutrition-related laboratory tests or procedures, as per the facilities protocol, 
but the RD could also discuss the nutritional care provided with the physician and 
document the order in the medical record.  Ten-percent of respondents reported 
independent prescriptive authority (the RD was able to place an order without the 
physician).  Barriers to independent prescriptive authority included opposition from 
physicians and liability issues.  The investigators concluded that the majority of 
respondents did not have independent prescriptive authority, but valued the ability to 
have prescriptive authority.  Limitations of this study included the low response rate, bias 
secondary to access to technology and inability to distinguish between responders and 
non-responders to the survey.  In addition, respondents may have completed the survey 
more than one time.  This study contributed more information regarding RD prescriptive 
practices and the roles of RDs in acute care settings.  The results of this study indicate 
that physician opposition is a main barrier to independent prescriptive authority even 
though there are many benefits to increased prescriptive authority, which include: timely 
implementation of nutrition-related orders, increased quality of care and recognition of 
RD expertise.  The researchers of this study suggested that a higher level of prescriptive 
authority may require the RD to meet additional educational competencies during their 
training and that future research should focus on identifying these additional 
competencies necessary for higher prescriptive authority, so that a curriculum of 
continuing education models could be provided to support RDs with the increased 
responsibilities associated with prescriptive authority.  This study highlights the 
importance, benefits and barriers of the RD in achieving higher prescriptive authority.  
Depending on the prescriptive authority of RDs in New Mexico, they may only be 
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involved in the recommendations for EN support in their patients with active CD and 
may not be involved in the initiation and management of EN in their patients with active 
CD. 
 
Soguel et al. (39) conducted a prospective interventional study to investigate the clinical 
impact of a two-step interdisciplinary quality nutrition program.  The study participants 
included 572 patients that required greater than 72 hours in the Intensive Care Unit 
(ICU).  Subjects were predominately male (68%) with the mean age of 59 years.  The 
study intervention involved three periods: 1) baseline, 2) a bottom-up implementation of 
the protocol on feeding guidelines to increase the early delivery and amount of nutrition 
(calories) provided to ICU patients, and 3) the continued implementation of the feeding 
guidelines protocol with the additional presence of an RD in the ICU.  The daily energy 
balance difference between baseline and period 3 (protocol with RD presence) was 
significant (based on improved energy deficit from -5870 kcal/week to -3950 kcal/week, 
p < 0.001) with the cumulative energy balances of patients improving over all three 
periods.  The amount of days with nutrition therapy increased significantly (59% at 
baseline, 69% at implementation of bottom-up approach and 71% with the protocol in the 
presence of an RD, p <.0001) with less ICU days of patients receiving nothing by mouth 
or oral feeds (which were associated with decreased energy intake).  The researchers 
concluded that having an RD significantly improved the amount of energy provided in 
order to meet the ICU patients’ energy needs due to early detection of energy deficits, 
earlier introduction of nutrition therapy and the RD’s suggestion to use combined 
feedings to increase the energy provided to patients.  A limitation of this study was that 
patients in the first period of the study (baseline) were less sick and had a lower mortality 
rate, per the study investigators.  Therefore, the patients in period 1 had a better chance of 
receiving adequate caloric needs.  The results of this study support the need for an ICU 
feeding protocol and RD to manage and oversee the overall nutrition provided to ICU 
patients.  The implementation of the ICU feeding protocol with the involvement of the 
RD improved the amount of calories provided to ICU patients.  This study implies that 
having an RD can significantly improve nutritional status and prevent malnutrition in the 
acute care setting.  It is especially important for patients with active CD to be seen by an 
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RD due to their increased risk for malnutrition and weight loss and to optimize their 
energy and nutrient intake.   
 
Culkin et al. (36) evaluated the effectiveness of an intervention, which consisted of 
providing nutrition education materials and dietary counseling by an RD, on 
improvement in patient knowledge, oral intake, nutritional status and QOL in individuals 
with chronic intestinal failure (CIF).  Forty-eight patients participated in the study.  
Thirty-three received home PN and an oral CIF diet, five consumed an exclusive oral CIF 
diet, four received oral nutritional supplements in addition to a CIF diet, four received 
home intravenous fluids and a CIF diet and two received subcutaneous fluids in addition 
to a CIF diet.  The average age of the participants was 56 years, with females in the 
majority (65%).  Patients completed baseline and post-intervention questionnaires (to 
evaluate QOL and nutrition knowledge), as well as kept 3-day diet and GI-output diaries.  
The RD was present when the patients completed the questionnaires to ensure that 
participants were answering questions based on knowledge and not by referring to the 
educational booklet on CIF.  Also, the RD provided and explained the educational 
booklet about CIF, nutrition and medications to the patients.  The researchers found that 
energy intake improved (2129 kcal/day at baseline vs. 2341 post-intervention, p < .04), 
fat intake improved (93 g at baseline vs. 110 g post-intervention, p < .003) and that 
patients demonstrated increased knowledge (via scores obtained from the knowledge 
questionnaire on a scale of -100% to +100%) after the intervention with the RD (64.3% at 
baseline vs. 80.7% post-intervention, p < 0.001).  This study demonstrated that nutritional 
counseling by an RD when paired with nutrition education via written materials may 
significantly improve patient knowledge about nutrition and resulted in improved fat and 
energy intakes in patients with CIF.  However, it remains unknown if the written material 
or the RD alone could produce similar results and if improved patient nutritional 
knowledge led to any behavior changes or improvement in fat and energy intakes.  The 
researchers listed a number of factors that may affect patient knowledge, which included 
the RD’s empathy, knowledge, encouragement, realism, confidentiality, importance, 
explanation, listening skills, negotiation skills, time usage, non-verbal cues, appearance 
and prejudice.  It would be interesting if future studies could determine which factors 
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affect patient knowledge more than others, so that RDs could focus on improving their 
skills and effectiveness.  This study demonstrates the usefulness of the RD and written 
material to improve energy and fat intake and nutrition knowledge in individuals with GI 
conditions.  As in CIF, it is crucial that the RD be involved in the nutrition care of 
patients with active CD, not only to provide the patient with information on the benefits 
of using EN to prevent malnutrition and achieve remission, but to help the patient achieve 
an optimal nutrition status.   
 
These studies demonstrate that there is a need for standards of practice that are evidence-
based in the field of dietetics and emphasize that the RD is essential for providing 
appropriate MNT recommendations for their patients.   
Conclusion  
This literature review suggests that there is no difference in effectiveness of elemental 
and semi-elemental EN formulations in the treatment of patients with active CD.  
Additionally, polymeric EN formulations are recommended as the primary EN therapy in 
the treatment of adults with active CD to help improve nutrition status by promoting 
remission and aiding the prevention of weight loss and malnutrition (15, 17).  This 
emphasizes the importance of nutritional support in adult patients suffering from active 
CD.  However, there is limited published information regarding whether current 
guidelines for the care of patients with CD are being utilized by RDs who provide MNT 
to patients with active CD.  The articles discussed in this literature review emphasize the 
importance of the RD in providing MNT and nutrition education materials to improve 
nutrition knowledge, as well as medical and nutritional outcomes.  Additionally, it was 
discussed that RDs are underutilized in the care of patients with GI conditions, but that 
patients with GI conditions may value consultation with an RD.  With the limited 
research available on the appropriate nutritional therapy for patients with CD, it is 
difficult for the RD to provide evidence-based MNT.  The purpose of this research study 
is to compare the EN formulations that are currently recommended in the acute care 
setting by RDs in New Mexico for their patients with active CD to the current ESPEN 
and ASPEN clinical nutrition guidelines.   
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CHAPTER 3: METHODOLOGY 
Human Research Protections 
The study protocol was submitted to the University of New Mexico (UNM) Human 
Research Protections Office (HRPO) and Institutional Review Board (IRB) approval was 
obtained before the study commenced (Appendix A).   
Survey Design 
This study used a cross-sectional research design.  During the spring of 2011, a pilot 
survey was developed based on the ASPEN and ESPEN clinical nutrition guidelines and 
EN formula company online websites (Abbott Nutrition and Nestlé Nutrition) (40, 41).   
Pilot Study 
Six individuals participated in the pilot survey, they included: one dietetic intern, two 
UNM Nutrition Faculty Members and three RDs who were currently working at an acute 
care facility in Albuquerque, New Mexico.  The pilot study participants completed the 
eight-question multiple-choice answer questionnaire and demographic questions via an 
online survey and provided feedback via an evaluation form (Appendix B & C).  The 
pilot participants were given two weeks to complete the pilot questionnaire and 
evaluation form.  They received an initial, reminder and final e-mail with the HRPO 
approved cover letter attached to each e-mail.  Each e-mail described the purpose of the 
study, the amount of time that the survey was expected to take and explained that by 
completing the survey they indicated consent to participate in the study (Appendix D, E, 
F).  Based on the feedback collected from the pilot study, three questions were modified 
(questions 2, 5 & 6) and an additional question was added to include a comments section.  
The survey was modified to include eight multiple-choice questions about: 1) which EN 
formulations are recommended for patients with active CD, 2) reasons for choosing a 
particular type of EN formulation, 3) number of patients with active CD assessed 
annually, 4) number of patients with active CD treated with EN support annually, 5) 
clinical nutrition guidelines that RDs follow, 6) how EN is provided (sole diet, adjunct to 
oral diet or adjunct to PN), 7) the situations in which EN is provided and 8) challenges 
associated with providing EN to patients with active CD.  The survey also included six 
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questions about demographics and one question that allowed respondents to share 
additional comments (Appendix G).  The final online questionnaire (Appendix G) was 
developed using the online Survey Monkey website (Palo Alto, CA).   
Study Recruitment 
The target population for this study was RDs who treat patients with active CD in an 
acute care facility in New Mexico.  A list of possible participants was obtained via 
request from the Commission on Dietetic Registration (CDR).  CDR provided a list that 
included 390 RDs in New Mexico.  The CDR list was screened for potential study 
participants, who were selected based on specific eligibility criteria: they must be current 
licensed RDs who have treated or were currently treating adult patients with active CD 
(students, retirees and non-RDs were excluded), have an e-mail address that was on 
record with CDR and be actively practicing in an acute care facility in New Mexico 
during the spring of 2011.  After screening for potential participants, 109 RDs between 
the ages of 18 and 64 years were recruited to participate in this study.     
One-hundred nine potential participants received a recruitment e-mail that described the 
purpose of the study, the amount of time that the survey was expected to take and that by 
completing the survey they consented to participate in the study (Appendix C).  The 
recruitment e-mail contained the link to the online survey and the HRPO approved 
consent cover letter as an attachment, which indicated that by completing the 
questionnaire they were consenting to participate in the study (Appendix H).  Both the 
survey and initial recruitment e-mail indicated that only RDs that worked with adult 
patients with active CD in acute care facilities in New Mexico should participate in the 
study.  The RDs who were deemed eligible to participate received three e-mails in April 
and May 2011 including: one initial recruitment e-mail and two reminder e-mails within 
a period of three weeks explaining the purpose of the study, the importance of their 
feedback, that their participation in the study was crucial to the success of the study, 
reminders for them to complete the survey and that completion of the study questionnaire 
was voluntary and indicated informed consent to participate in the study (Appendix D, 
E, F).     
22 
 
Data Collection 
After modification of the questionnaire, the link to the online survey was e-mailed to the 
109 RDs in the state of New Mexico who met the study CDR screening eligibility 
criteria.  Eligible RDs received an e-mail asking them to complete a survey on the Survey 
Monkey website.  The HRPO approved cover letter and link to the electronic 
questionnaire were e-mailed to the RD sample in April and May of 2011.  Both the e-
mail and questionnaire were used as recruitment and screening tools for the study to 
ensure that participants fit the eligibility criteria.  Forty-five RDs responded to the initial 
and reminder e-mails indicating that they were not going to complete the survey because 
they did not fit the inclusion criteria.  Those RDs were deleted from the e-mail list and 
not included in the study sample.  Thirty-three completed surveys were screened for 
eligibility by the primary investigator (NH).  Ten respondents were excluded from data 
analysis because they were ineligible for the study: they reported in the comments section 
of the survey that they were not actively practicing dietetics, did not work in an acute 
care facility, reported that they could not appropriately answer the survey questionnaire 
or answered “I have not treated patients with active CD” to the first survey question.  
After exclusion, survey results were entered into a Microsoft Excel spreadsheet in 
preparation for statistical analysis.  The final data analysis was conducted on a total of 23 
respondents.  Excluding potential participants who were deemed ineligible (n = 55), the 
response rate to the survey was 42.6% (23 out of 54 potential respondents). 
Statistical Analysis 
The statistical software SPSS 21.0 (IBM Corporation, Armonk, New York) was used for 
all data analysis.  Statistical analyses were conducted using descriptive statistics, Fisher’s 
exact, Pearson’s χ2 and Cramer’s V tests as appropriate to examine the relationship 
between variables.  P < .05 was considered to be statistically significant.  Associations 
between the reported guidelines used by RDs, the EN formulations recommended for 
their patients with active CD and the RD’s age, gender, length of time practicing 
dietetics, location of employment, the patient population they work with, situations in 
which they recommend EN and the challenges associated with providing EN to patients 
with active CD were analyzed for statistically significant associations.  
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To analyze data obtained from the survey, responses were categorized into different 
groups for questions 1, 7 and 8 (Table 3).  Participants were allowed to choose multiple 
responses for questions 1, 2, 5, 7, and 8; therefore percentages of responses may be 
greater than 100%. 
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Table 3: Categorization of Data for Statistical Analysis 
*Question 1: EN Formulations 
Recommended to Patients with Active CD  
Formulas Recommended: Number of 
Responses 
Percentage of 
Responses 
Semi-Elemental/Elemental Formulations 
 
 Crucial 1.5 Cal 
 Optimental 
 Pivot 1.5 Cal 
 Peptamen 1.5 Cal 
 Peptamen AF 
 Peptamen OS 1.5 Cal 
 Perative 
 Vital HN 
 Vivonex RTF 
 Vivonex Plus 
 Vivonex TEN 
12 52.2% 
Polymeric Formulations 
 
 Diabetisource AC 
 Fibersource 
 Glucerna 1.2 Cal 
 Glucerna 1.5 Cal 
 Hi-Cal 
 Isosource 1.5 Cal 
 Jevity 1.2 Cal 
 Osmolite 1 Cal 
 Oxepa 
 Promote 
 Promote with Fiber 
 TwoCal HN 
2 8.7% 
Polymeric & Elemental/Semi-Elemental 
Formulations 
Both Polymeric and Semi-/Elemental 
Formulas 
5 21.7% 
No EN Formulation provided Typically do not recommend EN for CD 4 17.4% 
*Question 7: Situations in Which EN is 
Recommended  in Active CD 
All Situations Number of 
Responses 
Percentage of 
Responses 
Medical/Surgical Situations  Abscess/Fistula 
 Patient’s Level of Alertness 
 Patient with Inflammatory Stenosis of 
the Intestine 
 Patient is Intubated 
 Post-op 
 Pre-Surgical 
11 47.8% 
Nutritional Issues  Acute Inflammatory Stage with poor 
intake 
 Not tolerating an oral diet 
 Poor nutrient intake with weight loss 
of greater than 5% 
 Undernourished Patient 
18 78.3% 
Related to Steroids  Patient refuses steroids 
 As an adjunct to steroids 
2 8.9% 
Not Mentioned By RD n/a 2 8.9% 
*Question 8: Challenges Associated with 
Managing EN for Patients with Active CD 
All  Reported Perceived Challenges Number of 
Responses 
Percentages 
of Responses 
Tolerance Issues  Patient tolerance to EN 
 Re-establishing Oral PO 
 Limited Time 
 Fistulas 
15 65.2% 
Knowledge Issues  Limited Available Research 
 MD/Physician Resistance 
7 30.4% 
Access Issues  Formula Cost 
 Limited Formulary 
7 30.4% 
Patient Attitude  Patient Compliance 
 Patient Acceptance of EN or PN 
8 34.8% 
None  RD did not know 
 Not mentioned by RD 
2 8.7% 
*Participants were able to choose more than one answer for this question.  Percentages may total greater than 100%. 
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CHAPTER 4: RESULTS 
Participant Demographics 
Of the 54 RDs in the state of New Mexico that were potentially eligible for this study, a 
total of 23 participants (42.6% response rate) fit the inclusion criteria and completed the 
survey.  The respondent demographics (Table 4) included: 82.6% (n = 19) of respondents 
were females, 91.3% (n = 21) were Caucasian and 9% (n = 2) were Hispanic/Latino, 
73.9% (n = 17) were working at an urban/suburban acute care facility at the time of the 
study compared to 26.1% (n= 6) at a rural location, 69.6% (n = 16) had been practicing RDs 
for more than 15 years, 56.5% (n = 13) worked solely with the adult population and 43.5% 
(n = 10) with both the pediatric and adult population.  All respondents were between the 
ages of 26 and 64 years. 
 
Table 4: Participant Demographics 
Participant Gender Age  
(in years) 
Ethnicity Years 
Practicing 
Dietetics 
Acute Care Facility 
Location 
Patient Population  
 
1 Female 26 – 40  Caucasian 1 – 5 Rural Pediatric and Adult 
2 Female 41 – 64  Caucasian 16 – 30 Urban Adult 
3 Female 26 – 40 Caucasian 1 – 5 Urban Adult 
4 Female 41 – 64 Caucasian >  30 Rural Pediatric and Adult 
5 Female 41 – 64 Caucasian 16 – 30 Urban Adult 
6 Female 41 – 64 Caucasian 6 – 15 Urban Pediatric and Adult 
7 Male 41 – 64  Caucasian 16 – 30 Urban Adult 
8 Female 41 – 64 Caucasian 16 – 30 Urban Adult 
9 Female 41 – 64 Caucasian 16 – 30 Rural Adult 
10 Female 41 – 64 Caucasian >  30 Urban Adult 
11 Female 26 – 40 Caucasian 6 – 15 Suburban Pediatric and Adult 
12 Female 26 – 40 Caucasian 1 – 5 Suburban Adult 
13 Female 41 – 64 Caucasian >  30 Urban Adult 
14 Male 41 – 64 Caucasian 16 – 30 Rural Pediatric and Adult 
15 Male  41 – 64 Caucasian 16 – 30 Urban Pediatric and Adult 
16 Female 26 – 40 Caucasian 6 – 15 Suburban Pediatric and Adult 
17 Female 41 – 64 Caucasian 16 – 30 Urban Pediatric and Adult 
18 Female 41 – 64 Caucasian >  30 Urban Adult 
19 Female 41 – 64 Hispanic/Latino 16 – 30 Urban Adult 
20 Female 41 – 64 Caucasian >  30 Rural Adult 
21 Female 26 – 40 Caucasian 6 – 15 Suburban Pediatric and Adult 
22 Female 41 – 64 Hispanic/Latino 41 – 64 Urban Adult 
23 Male 41 – 64 Caucasian 41 – 64 Rural Pediatric and Adult 
Participant Completion of Questionnaire 
Of the 23 participants included in this study, 65% (n = 15) completed the survey within 
the first week after the initial e-mail had been sent, 22% (n = 5) of participants completed 
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the survey during the second week after receiving the reminder e-mail and 13% (n = 3) of 
participants completed the survey during the third week after receiving the final e-mail 
reminder.  This suggests that most participants respond and participate in survey research 
within the first week of recruitment. 
RD Practices in New Mexico 
Eighty-three percent of respondents reported that they assess between one and ten 
patients with active CD annually (n = 19), with only one participant (4.3%) reporting 
assessing eleven or more patients with active CD annually and three respondents (13%) 
reporting that they typically do not assess any CD patients annually.  Sixty-five percent 
(n = 15) of respondents reported that they treat one to five patients with active CD with 
EN support annually and 34.8% (n = 8) of participants reported that they typically do not 
treat any CD patients with EN support annually.  Of the 23 RDs included in this study, 
four (17.4%) respondents reported that they do not typically recommend EN for their 
patients with active CD.  Of the RDs that recommend EN formulations (n = 19) for their 
patients with CD, 89.5% (n = 17) reported using elemental and semi-elemental 
formulations and 36.8% (n = 7) reported using polymeric EN formulations for their 
patients with active CD.   
 
The ESPEN, ASPEN and AND NCM clinical nutrition guidelines were the most 
commonly reported guidelines used by RDs for the nutritional assessment and MNT of 
patients with CD.  Approximately 26% (n = 6) of respondents reported using ASPEN 
clinical nutrition guidelines, 22% (n = 5) reported using ESPEN clinical nutrition 
guidelines, and 22% (n = 5) reported using AND NCM clinical nutrition guidelines.  
Other guidelines reported to be used for the nutritional assessment and MNT of CD 
patients consisted of: guidelines provided by the RD’s acute care facility (8.7%, n = 2) 
and Critical Care guidelines (4.4%, n = 1).  Based on this study’s results, the guidelines 
reported to be most commonly used are the ESPEN, ASPEN and AND NCM guidelines; 
however, most RDs reported that they typically use semi-elemental and elemental 
formulations (52%, n = 12) for their patients with active CD. 
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Most RDs reported following guidelines for the MNT of patients with active CD, with 
only 34.7% (n = 8) of participants reporting that they did not follow any clinical nutrition 
guidelines or did not know the guidelines that they were currently following.  Forty-four 
percent (n = 10) of respondents reported that they use ESPEN and ASPEN guidelines; 
however use of these guidelines did not necessarily mean that participants used the 
recommended standard (polymeric) formulations for their patients with CD (χ2 [1] = .765, 
p = .382).  However, those that reported using ASPEN guidelines were more likely to 
report using polymeric EN formulations (χ2 [1] = 5.033, p = .025, effect size = .468).   
 
RDs that reported using ASPEN guidelines were more likely to be working at an urban 
location (χ2 [2] = 6.244, p = .044, effect size = .521).    Interestingly, no individuals that 
work with both the adult and pediatric population reported using ASPEN guidelines (χ2 
[1] = 6.244, p = .012, effect size = .521).  RDs that reported using ESPEN and ASPEN 
clinical nutrition guidelines were more likely to provide EN support annually to their 
patients with active CD (χ2 [1] = 9.436, p = .002, effect size = .641).   
 
There was a statistically significant association between the number of years that the RD 
has been practicing dietetics (1 – 15 years vs. 16 - 30 years or more) and the use of 
ESPEN guidelines (χ2 [1] = 5.759, p = .016, effect size = .50), with RDs who reported 
that they have been practicing dietetics for 15 years or less (34.8%, n = 8) being more 
likely to report using ESPEN guidelines compared to RDs that have been practicing for 
greater than 15 years (65.2%, n = 15).   
 
In general, RDs reported that when they provide EN support, it is most commonly 
provided as an adjunct to oral intake (56.5%, n = 13).  Twenty-six percent (n = 6) of RDs 
reported that they provide EN as the patient’s sole intake and 17.4% (n = 4) as an adjunct 
to PN.  Following ESPEN guidelines was not found to be statistically significant in 
providing EN in a specific way (sole nutrition, adjunct to oral or adjunct to PN, χ2 [2] = 
2.277, p = .32).   
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Forty-four percent of respondents (n = 10) reported that the “most important” reason for 
helping them to determine which particular EN formulations to use was that the particular 
formulation is on their hospital formulary.  Thirteen percent (n = 3) of respondents 
reported that the “most important” reason for helping them to determine which particular 
EN formations to use was that the formulation contained a specific ingredient (Figure 1).   
Figure 1: “Most Important” Reasons for Choosing a Particular EN Formulation 
 
 
Ranked as the top “important” reason for 30.4% (n = 7) of respondents was that it was an 
elemental EN formulation.  Tied for third place, respondents reported that both the 
macronutrient content (22%, n = 5) and price of a particular EN formulation (22%, n = 5) 
were their most “neutral” reasons for deciding upon an EN formulation (Table 5). 
Table 5: Ranking of the Reasons Why RDs Choose a Particular EN Formulation 
Reasons for Choosing a 
Particular EN Formulation 
"Most 
Important" "Important" "Neutral" 
"Not 
Important" 
"Least 
Important" 
Not 
Ranked 
Price 3 (11%) 0 (0%) 5 (24%) 1 (10%) 5 (26.3%)  9 (22%) 
Contains a Specific Ingredient 5 (19%) 3 (15%) 4 (19%) 3 (30%) 1 (5.5%) 7 (17%) 
Macronutrient Content 3 (11%) 3 (15%) 5 (24%) 2 (20%) 2 (10.5%) 8 (20%) 
Elemental Formulation 4 (15%) 7 (35%) 2 (9.5%) 1 (10%) 5 (26.3%) 4 (10%) 
Polymeric Formulation 2 (7%) 3 (15%) 4 (19%) 2 (20%) 2 (10.5%) 10 (24%) 
On Hospital Formulary 10 (37%) 4 (20%) 1 (4.5%) 1 (10%) 4 (21%) 3 (7%) 
Total Responses For Each 
Ranking 27   20 21 10 19 41 
* Participants were not required to rank each reason listed.  Bolded responses indicate the top ranking for each reason.  
Percentages were calculated based on the total number of responses for each ranking.  
Percentages reflect the total number of responses for the “most important” reason for 
choosing a particular EN Formulation. 
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RDs reported medical, surgical, corticosteroid, and nutritional reasons for using EN for 
their patients with active CD (Figure 2).  Nutritional issues were the most commonly 
reported situations in which RDs reported recommending EN for their patients with 
active CD (78.3%, n = 18), specifically when the patients are undernourished (69.5%, n = 
16) or have a poor nutrient intake with 5% or greater weight loss (56.5%, n = 13).   
Figure 2: Situations in Which EN is Recommended for Patients with Active CD 
 
RDs reported their perceived challenges with the management of patients with active CD.  
The reported challenges consisted of access, knowledge, tolerance and patient attitude 
issues (Figure 3), with the greatest perceived challenges being: patient tolerance to EN 
(56.5%, n = 13), followed by patient compliance (34.8%, n = 8), the cost of the EN 
formulation (26.1%, n = 6) and limited research on the area of CD and EN (21.7%, n = 
5).  Access issues were reported by 30.4% (n = 7) of respondents; these included formula 
cost (26.1%, n = 6) and limited formulary (4.3%, n = 1) at their acute care facility.  
Knowledge issues were reported by 30.4% (n = 7) of respondents, which included limited 
research in the area of CD (21.7%, n = 5) and physician resistance (13%, n = 3).  
Tolerance issues were reported by 65.2% (n = 15) of respondents and included 
intolerance to EN (60.9%, n = 14), re-establishing intake by mouth (4.3%, n = 1) and 
limited time (to assess and follow-up with the patient, 4.3%, n = 1).  Patient attitudes 
were also reported to be an issue by 34.8% (n = 8) of participants, which included the 
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patient’s compliance with EN recommendations (34.8%, n = 8) and their acceptance of 
EN or PN support (4.3%, n = 1). 
Figure 3: Challenges Associated with EN Management in Active CD 
 
The χ 2 test revealed that there was a statistically significant association between where 
the RD was employed and report of access challenges (χ2 [1] = 5.033, p = .025, effect size 
= .468).  Specifically, individuals who worked in a rural location reported more access 
issues (cost of EN and limited EN formulary) than individuals who were employed at an 
urban/suburban location.  Practicing dietetics for less than 15 years had a statistically 
significant association with being less likely to be currently practicing at an urban 
location (χ2 [2] = 9.662, p = .008, effect size = .648).   
Lastly, eight RDs provided additional comments on the use of EN in patients with active 
CD (Appendix I).  These comments discussed the need for simple, bullet-point guidelines 
for use of EN in patients with active CD; as well as guidelines for the assessment, 
diagnosis and MNT for these patients. 
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CHAPTER 5: DISCUSSION 
The purpose of this research study is to compare the current practices of RDs in New 
Mexico in caring for their patients with active CD to the current ESPEN and ASPEN 
clinical nutrition guidelines.  Based on the results of this study, we find that the majority 
of responding RDs employed at acute care facilities in New Mexico fail to follow the 
current ESPEN and ASPEN clinical nutrition guidelines and recommendations for EN 
support in patients with active CD.   
 
Respondents reported that the most commonly used clinical nutrition guidelines used in 
the acute care setting for the nutritional assessment and MNT for their patients with 
active CD were the ASPEN, ESPEN and AND NCM clinical nutrition guidelines.  RDs 
that reported using ASPEN and ESPEN guidelines were more likely to report treating one 
to five patients with active CD with EN support annually.  Those RDs that did not report 
using ESPEN or ASPEN guidelines were more likely to report that they do not use EN 
support for their patients with active CD.  This suggests that RDs that don’t use the 
ASPEN and ESPEN clinical nutrition guidelines aren’t aware that EN support should be 
used in patients with active CD.   
 
This study revealed that RDs that have been practicing dietetics for less than 15 years 
were more likely to report using ESPEN clinical nutrition guidelines.  Recent dietetic 
graduates may be more up-to-date with the current research in dietetics than the RDs who 
have been practicing for a longer period of time.  RDs who are further away from their 
initial training may need continuing education in this area of EN support for CD patients.  
This may also be explained by the fact that recent RDs are relying more on the available 
clinical nutrition guidelines because of their lack of experience. 
 
None of the RDs who reported following ESPEN guidelines reported using polymeric EN 
formulations.  ESPEN guidelines are substantially more detailed than ASPEN guidelines 
in their description of providing EN support to patients with active CD.  It is concerning 
that those RDs that reported using ESPEN guidelines are not utilizing the polymeric EN 
formulation recommendations, especially since the ESPEN guidelines are readily 
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available on PubMed’s online journal database.  It would be beneficial for future research 
to examine why known guidelines are not being followed.  For example, the guidelines 
may be difficult to understand, individuals may not be aware that the guidelines exist or 
other factors (access, knowledge, patient issues, etc.) may be preventing RDs from 
recommending polymeric EN formulations to their patients.  The results of this study 
suggest that those RDs who reported using ESPEN guidelines, were also more likely to 
report practicing dietetics for less than 15 years, therefore were more likely to report 
access issues because they were less likely to be employed at an urban location; hence 
access issues may be factors decreasing RD compliance with ESPEN guidelines. 
 
The data collected from this study suggests that most RDs recommend semi-elemental 
and elemental EN formulations when they recommend EN for their patients with active 
CD.  It is important that future research be conducted to evaluate the reasons why RDs 
are recommending elemental and semi-elemental EN formulations more frequently than 
polymeric EN formulations, because current nutrition guidelines (ESPEN and ASPEN) 
recommend the use of polymeric EN formulations.  Additionally, RDs reported that the 
top “important” reason for choosing a particular EN formula was that it was an elemental 
EN formulation.  It is possible that even though polymeric formulations are the primary 
EN therapy of choice, RDs may consider elemental and semi-elemental EN formulations 
superior to polymeric EN formulations.  One reason may be that many RDs believe that 
elemental EN formulations may be better tolerated due to better absorption because of 
advertising by formula companies who promote the use of their formulas for the use of 
active CD due to possible malabsorptive and malnutrition issues.  Also, an NG-tube may 
be easily placed in the acute care setting, so palatability of the EN formulation may not 
be an issue.  Additionally, polymeric formulas may not be provided because research on 
elemental diets has been positive, with published research demonstrating that individuals 
who receive elemental diets may have decreased total bacteria per gram of feces, which 
may reduce intestinal inflammation.  This data suggests that even though current 
nutrition guidelines recommend use of polymeric EN formulations; it appears, at least in 
New Mexico, that these guidelines are not being utilized. 
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On the other hand, RDs that reported using ASPEN guidelines were more likely to report 
recommending polymeric EN formulations for their patients with active CD.  Also, RDs 
that reported using ASPEN guidelines reported that they only assessed and treated adult 
patients and were more likely to be working at an urban location.  It appears that those 
RDs that reported using ASPEN guidelines are implementing the recommendations in the 
guidelines more often than those who reported using ESPEN guidelines.  This may be 
because ASPEN is a membership organization and it may be doing a better job of 
providing support and explanations of its guidelines or possibly those RDs employed at 
urban locations have more access to the ASPEN clinical nutrition guidelines and larger, 
better stocked formularies.  ASPEN charges fees and requires membership in order to use 
their clinical nutrition support tools.  Either way, it is interesting that none of the RDs that 
work with both the adult and pediatric population reported using ASPEN guidelines.  It is 
possible that these RDs are not aware that ASPEN provides guidelines for use in the 
pediatric population.  It would be beneficial for further research to be conducted to 
determine why RDs that work with both pediatric and adult patient population are not 
using ASPEN guidelines.  It is a concern, since RDs that work with both the pediatric and 
adult population made up a large percentage of the RDs that responded to the survey and 
only half reported using any clinical nutrition guidelines at all. 
 
The “most important” reason that RDs reported for choosing a particular EN formula, is 
that the formula is available on their hospital formulary list.  It is easier to use formulas 
that are readily available on the acute care facility’s formulary.  At some facilities, the 
CNM decides which formulations are available on the formulary; it would be beneficial 
for these individuals to be educated on ASPEN and ESPEN clinical nutrition guidelines.  
Typically, formulas not listed on the acute care facility’s formulary are still available for 
the RD to use.  However, time and cost become issues, as the specific formula must be 
ordered and shipped to the facility, which takes additional time to receive and dispense 
and can increase the cost the facility spends on EN. 
 
Most RDs reported that they provide EN as an adjunct to oral intake, rather than sole 
intake or as an adjunct to PN.  This suggests that EN is being provided to patients with 
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active CD to improve their nutritional intake.  RDs reported that situations, in which they 
recommend EN to their patients with active CD include: medical, surgical, nutritional and 
corticosteroid issues.  The most commonly reported situation in which RDs will provide 
EN support is a nutritional issue, such as an undernourished individual or an individual 
with poor nutrient intake and greater than 5% weight loss.  Most RDs are concerned 
about the nutritional status of their patients, as it is the RD’s role to promote adequate 
nutrient intake and prevent future complications through nutrition support and MNT.   
 
RDs reported multiple challenges associated with the management of EN for their 
patients with active CD.  These challenges included: tolerance issues, patient’s attitude 
towards EN, access issues and knowledge issues (physician resistance to use of EN and 
limited available research on the use of EN in patients with active CD).  The major 
perceived challenge was tolerance issues: intolerance to EN and limited time to assess 
and monitor patients.  These issues are common at any hospital, as it is the RD’s job to 
manage EN intolerances and inform the physician of current research on MNT for 
specific conditions.  Limited time is an issue everywhere because people are multitasking 
more and have less time to complete their tasks (42).  Lastly, access challenges (limited 
formulary and cost of EN formulation) were more likely to be reported by RDs that were 
employed in rural locations.  New Mexico has a dispersed rural population.  It would be 
beneficial to know what is causing the specific access challenges (maybe EN 
formulations are only delivered once a month, cost may be increased for EN formulations 
at a rural location and other issues may be involved) in acute care facilities located in 
rural locations because patient care should not be compromised due to the large distances 
involved. 
 
Some RDs who responded to the survey provided comments on EN use in their patients 
with active CD.  Based on their comments it appears that simple, bullet-point guidelines 
could be beneficial in promoting the use of EN for patients with active CD because RDs 
could use them for a reference, not only for themselves, but could provide them to the 
physicians that they work with to promote the physician’s use of EN formulation 
recommendations for patients with active CD.   
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The results of this study suggest that RDs do not follow ESPEN and ASPEN clinical 
nutrition guidelines in the care of their patients with active CD.  Based on the published 
literature on EN and active CD, it appears that EN is effective in preventing malnutrition 
and inducing remission in patients with active CD when used in conjunction with other 
therapies in the adult population.  It would be beneficial for simple guidelines to be 
provided to RDs through state licensure organizations, continuing educational credits or 
dietetic practice groups as this would provide a way to create a more uniform standard of 
practice for patients with active CD.  RDs could continue to search out additional 
guidelines for their patients with active CD, but they would at least be aware of what is 
recommended by the state in which they are licensed.   
Study Strengths 
This study provides much needed information, in an area of research where there have 
been few, if any published articles that have evaluated whether RDs use clinical nutrition 
guidelines for their patients with active CD in the acute care setting.  The major strength 
of this study is that it fills a gap in the literature regarding how RDs in New Mexico 
practice in the acute care setting in regards to EN recommendations for their patients with 
active CD. 
Study Limitations 
This study has several limitations. The data collected relied on self-report via an online 
survey questionnaire; therefore it is impossible to know if what RDs reported is truly how 
RDs practice at their acute care facility.  Additionally, multiple exclusion criteria (such 
as: requiring participants to be current RDs [not students, retirees or RD eligible], 
actively practicing dietetics, currently residing and working in New Mexico at an acute 
care facility, registered with CDR with a working e-mail and have worked with adult 
patients with active CD) were used in selecting the study participants, thereby possibly 
limiting the generalizability of the study results.  Generalizability is limited because of 
the small sample size and limited geographic area covered, as these data only represent 
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those RDs who actively provide MNT to patients with active CD in acute care facilities 
in New Mexico and cannot be generalized to all RDs who treat patients with active CD. 
 
Another limitation is that this study consisted of a very small sample size which impacts 
the statistical power of a research study.  Low power decreases the possibility of 
detecting significant relationships between variables.  In addition, a small sample size 
limits the ability to conduct multivariate analysis and to control for potential confounders.   
 
A limitation of this study is the low response rate to the survey (42.6 %).  A low response 
rate could be attributed to: e-mail addresses that did not work; individuals who moved out 
of state, retired, changed employment or passed away; and individuals who had limited 
time to complete the survey, lack of interest in the study, limited access to the internet or 
reservations about participating in the study.  This may hinder the generalizability and 
reliability of the results.  We cannot assume that the results of this survey are 
representative of all RDs caring for patients with CD in acute care facilities in New 
Mexico.   
 
Based on the way the questionnaire was worded, the exact number of patients assessed 
and treated with EN support annually is not known, only an estimated range of the 
patients assessed and treated annually.  The questionnaire provided pre-determined 
ranges for the responses to the questions: “On average, how many patients with active 
CD do you assess on a yearly basis?” and “On average, how many patients with active 
CD do you treat with EN support on a yearly basis?”; hence, it is not known if one patient 
or ten patients with active CD were assessed annually and if one or five patients with 
active CD were treated with EN support annually.  Allowing the RDs to respond with the 
exact amount of patients with active CD assessed and treated annually, as well as the 
number of patients that they generally assess and treat with EN, would have increased our 
ability to use this variable in statistical analysis. 
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Additional Research 
More research should be conducted on a larger scale, for example on a national level, to 
determine how RD’s in an acute care setting provide MNT for patients with active CD.  
Future research should evaluate the reasons RDs have for not using clinical nutrition 
guidelines and what MNT or EN recommendations that these RDs usually make for their 
patients with active CD.  Not utilizing clinical nutrition guidelines has huge implications 
to the field of dietetics.  RDs are taught to follow current evidence-based MNT, so why 
are they not following the current clinical nutrition guidelines?  Additionally, it would be 
interesting to test RD awareness of clinical nutrition guidelines because it will help in 
making MNT in the acute care setting more uniform.  It is possible that RDs do not 
understand the current clinical nutrition guidelines, there is a lack of availability of 
guidelines (due to cost of obtaining guidelines or membership requirements), that RDs 
are hesitant to follow guidelines, or that outside factors (access, knowledge, patient 
issues, etc.) are preventing the RD from following the guidelines.   
 
It is also possible that advertising by formula companies affects the RD’s decision when 
choosing a formulary for the acute care facility for which they are employed and when 
recommending EN for a patient with active CD.  It would be both interesting and 
beneficial for research to be conducted on the affect of advertising by formula companies 
on the RD’s decision of which EN formulation to use. 
 
Lastly, RDs employed in rural locations reported increased access issues (limited 
formulary and increased cost of EN).  More research could examine what is contributing 
to these problems and determine ways to prevent these access issues from occurring in 
the future. 
Conclusion 
The purpose of this study was to identify which EN formulations are currently 
recommended in the acute care setting by RDs in New Mexico for their patients with 
active CD and to compare these recommended formulations to the current ASPEN and 
ESPEN clinical nutrition guidelines.  Overall, most RDs who participated in this study 
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did not follow the ESPEN and ASPEN clinical nutrition guidelines for EN support in 
patients with active CD.  We reject the hypothesis that RDs that work in acute care 
facilities in New Mexico follow the current clinical nutrition guidelines (ASPEN and 
ESPEN) and recommendations for EN support in patients with active CD.   
 
Most RDs reported following clinical nutrition guidelines.  Even though ESPEN and 
ASPEN guidelines were the most commonly used guidelines reported by RDs, use of 
these guidelines did not necessarily mean that RDs used the recommended standard 
(polymeric) formulations for their patients with active CD.    The most commonly 
recommended EN formulations by RDs were semi-elemental and elemental formulations 
for patients with active CD.  This suggests that the awareness of the guidelines and their 
recommendations are not being translated into practice.  Future research should examine 
understanding of guidelines used, why semi-elemental and elemental formulations are 
being recommended over polymeric formulations, ways to improve standards of practice 
for EN use in patients with active CD and the health outcomes of patients with active CD 
depending on the nutritional therapy that they receive during their treatment at an acute 
care facility.   
Addendum 
ASPEN and ESPEN clinical nutrition guidelines have recently been updated.  ASPEN 
guidelines were updated in 2012, but the guidelines have not changed (20).  ESPEN 
guidelines were updated in 2011 (43).  Because this study’s questionnaire was 
administered prior to the update of the ASPEN and ESPEN clinical nutrition guidelines, 
the guidelines that were in use during the time of this study were used as a reference for 
the statistical analysis of this study (15, 26). 
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APPENDICES  
APPENDIX A: IRB EXEMPT APPROVAL FORM 
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APPENDIX B: PILOT QUESTIONNAIRE 
 Enteral Nutrition 
Registered Dietitian Clinical Nutrition Practices Questionnaire 
Dear Respondent,  
This study is being conducted by Nicole Horvath, a graduate student 
and Dietetic Intern, and Deborah Cohen, an Assistant Professor and 
Advisor, at the University of New Mexico. We are conducting this study 
in order to better understand the practices of Clinical Registered 
Dietitians who are employed in New Mexico acute care facilities. 
Specifically, we are interested in the Clinical Registered Dietitian 
prescriptive practices of enteral nutrition formulas for patients with active 
Crohn's disease in New Mexico. This research will help Clinical 
Dietitians to better understand how to treat Crohn's disease in New 
Mexico. The results of this study will be provided to survey respondents 
by the winter of 2011. 
 
Since the validity of the results depend on obtaining a high response 
rate, your participation is crucial to the success of this study. The 
questionnaire will take approximately 5-10 minutes to complete. 
 
Your completion of this questionnaire indicates your consent to 
participate in this study. Please be assured that your responses will be 
held in the strictest confidence. If the results of this study were to be 
written for publication, no identifying information will be used. 
 
We will send the compiled results in an email to you as soon as the 
study is completed and compiled. Our hope is that this study may 
increase your understanding of what enteral formula to prescribe to your 
patients with Crohn's disease. 
 
Thank you for your participation. 
Sincerely, 
Nicole Horvath 
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1. When recommending an enteral nutrition product for your patients who are admitted 
to the hospital with active Crohn’s disease, which of the following formula(s) do you 
most often recommend? (check all that apply) 
Diabetisource AC ___     Fibersource ___  
Glucerna 1.0 Cal ___     Glucerna 1.2 Cal ___ 
Glucerna 1.5 Cal ___     HI-CAL ___ 
Isosource 1.5 Cal ___     Jevity 1.2 Cal ___    
Optimental ___     Osmolite 1 Cal ___  
Oxepa ___       Peptamen AF___    
Peptamen 1.5 Cal ___     Peptamen OS 1.5 Cal ___   
Peptamen with Prebio ___     Perative ___     
Pivot 1.5 Cal ___      Promote ___ 
Promote with Fiber___    TwoCal HN ___  
Vital HN ___      Vivonex Plus ___  
Vivonex RTF ___     Vivonex TEN ___     
Other ________________________________________ (List Specific Formula)  
2.  What are the reasons you choose a particular enteral formula? [Rank the following 
reasons  from 1 (most important) to 5 (least important)] 
Price ___ 
Contains a specific ingredient ___ 
Macronutrient Content ___ 
Elemental Formula ___ 
Polymeric Formula ___ 
On Hospital Formulary ___ 
3.  On average, how many patients with active Crohn’s disease do you assess yearly? 
(select from ranges) 
0-10   ________ 
11-20 ________ 
21-30 ________ 
>30    ________ 
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4.  On average, how many patients with active Crohn's disease do you treat with enteral 
nutrition support yearly? (select from ranges) 
       0-5 ________ 
      6-10 _______ 
     11-20 ______ 
     21-30 ______ 
      >30 _______ 
5. Do you use clinical nutrition guidelines for the nutritional assessment and medical 
nutrition therapy of Crohn’s disease patients at your facility?  
Yes ___ 
No ___ 
Don’t know ___ 
 If Yes, Which clinical guidelines to you use?  
European Society for Parenteral and Enteral Nutrition (ESPEN) nutritional 
guidelines ___ 
Guidelines provided by your acute care facility ___ 
Other ___ (list specific guidelines) _______________________________  
6. When providing enteral nutrition support, would you say that enteral nutrition is used 
primarily as means of providing the sole support of nutrition or as an adjunct to oral 
intake: 
 Adjunct to oral intake ___ 
Sole source of nutrition ___ 
7. Enteral Nutrition is recommended during which of the following situations? (check 
all that apply): 
Steroid induced hormone imbalance ___ 
 Patient refuses steroids ___ 
Undernourished patient ___ 
As an adjunct with steroids ___ 
Patient with inflammatory stenosis of the small intestine ___ 
Pre-surgical ___ 
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Post-operative ___ 
Obstruction ___ 
Abscess ___ 
Poor nutrient intake with a weight loss >5% ___ 
Other: Please list __________________________________________________ 
8. What are your perceived challenges associated with the management of patients with 
active Crohn’s disease that receive Enteral Nutrition? (choose from the following list) 
Limited Nutrition Research/Guidelines regarding enteral nutrition support and 
Crohn’s disease ___ 
Cost of the enteral formula ___ 
Patient tolerance to Enteral Nutrition ___ 
Patient compliance ___ 
Other ___________________________________________ 
Demographic Questions 
9. What is your gender?  Male____  Female____ 
10. What is your ethnicity? (select from list) 
American Indian ___   Caucasian___ 
Hispanic or Latino___  African American___ 
Asian ___    Pacific Islander ___ 
Other: ______________ 
11. What is your age? 18-25___  26-40___  41-64___ 65+___ 
12. What is the geographical location in which you work? (select from list) 
Rural (pertaining to less-populated, non-urban areas) ___ 
Suburban (relating to the outlying part of a city or town) ___ 
Urban (relating to the city) ___ 
13. How long have you been a practicing Registered Dietitian?   
 1-5 years ___ 6 –15 years ___  16 – 30 years ___    30 years ___ 
 
*Thank you for completing the survey.  Please click on SUBMIT to send answers to be 
compiled with other survey results. 
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Evaluation of Survey: Registered Dietitian Clinical Nutrition Practices 
 
 
Directions:  
 Please complete this evaluation form as you do the survey. Your feedback is very 
valuable; please feel free to add additional comments and suggestions directly on 
the survey. 
 Return survey and evaluation form in the enclosed stamped envelope no later than 
April 15, 2011 to Nicole Horvath. Thank you very much for your time and input. 
 
1. How long did it take you to complete the survey? 
____5-10 minutes 
____10-15 minutes 
____15-20 minutes 
____longer than 20 minutes 
 
2. Did you have any trouble understanding any of the questions? 
____yes 
____no 
 
If yes, which questions were difficult: _____________________________ 
 
3. Would you recommend changing any of the questions? 
____yes 
____no 
 
    If yes, which questions would you change? __________________________ 
 
4. Are there any questions you would eliminate? 
____yes 
____no 
 
If yes, which question(s) would you eliminate? ________________________ 
 
5. Are there any questions you would add? 
____yes 
____no 
 
If yes, what question(s) would you add? ______________________________ 
 
6. Are there any other comments you would like to make regarding this survey? 
 
__________________________________________________________________
__________________________________________________________________
__________________________________________________________________
_________________________________ 
__________________________________________________________________
__________________________________________________________________
__________________________________________________________________
_________________________________ 
 
Thank you very much for your feedback! 
 
 
APPENDIX C: EVALUATION OF PILOT QUESTIONNAIRE 
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APPENDIX D: INITIAL RECRUITMENT E-MAIL 
Hello, 
I am a graduate student and Dietetic Intern currently conducting a study via an online survey with the 
help of Deborah Cohen, DCN, RD, Assistant Professor in the Nutrition Program at the University of New 
Mexico.  The purpose of this study is to identify the current practices of Clinical Registered Dietitians 
who work with adult Crohn’s disease patients in acute care facilities in New Mexico.  This survey 
consists of 10 questions and should take approximately 5-10 minutes to complete.  Please complete 
the survey before May 13, 2011, the last day of my Dietetic Internship. 
Please click on the following link to access the survey: http://www.surveymonkey.com/s/3JSZH75.  The 
survey is titled: “Practices of Registered Dietitians in New Mexico Regarding Enteral Nutrition in Patients 
with Crohn’s disease”.  This study has been approved by the University of New Mexico Institutional 
Review Board.  By completing this survey you are indicating your consent to participate in this study.  
Thank you for your participation, 
Nicole Horvath  
Graduate Student & Dietetic Intern 
University of New Mexico 
(505)610-4623 
nhorvath@unm.edu 
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APPENDIX E: REMINDER E-MAIL 
Hello, 
If you have not already taken the opportunity to complete the survey “Practices of Registered 
Dietitians in New Mexico Regarding Enteral Nutrition in Patients with Crohn’s Disease”, please 
take the time now.  The purpose of this study is to identify the current practices of Clinical 
Registered Dietitians who work with adult Crohn’s disease patients in acute care facilities in New 
Mexico.  This survey consists of 10 questions and should take approximately 5-10 minutes to 
complete.  Please complete the survey before May 13, 2011, the last day of my Dietetic 
Internship. 
Click on the following link to access the survey: http://www.surveymonkey.com/s/3JSZH75.  The 
survey is titled: “Practices of Registered Dietitians in New Mexico Regarding Enteral Nutrition in 
Patients with Crohn’s disease”.  This study has been approved by the University of New Mexico 
Institutional Review Board.  By completing this survey you are indicating your consent to 
participate in this study.  
In order to have a representative sample of Clinical Registered Dietitians in New Mexico, your 
participation is crucial to the success of this study. 
Thank you for your participation, 
Nicole Horvath  
Graduate Student & Dietetic Intern 
University of New Mexico 
(505)610-4623 
nhorvath@unm.edu 
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APPENDIX F: FINAL REMINDER E-MAIL 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Hello, 
 
Over the past two weeks, I have been collecting data via a survey for a study about the 
current practices of Clinical Registered Dietitians who work with adult Crohn’s disease 
patients in acute care facilities in New Mexico.  
 
If you haven't yet filled out the survey, would you please take a few minutes now to do so?  
This is the last week to complete the survey.  I would appreciate receiving your response by 
May 13, 2011, the last day of my Dietetic Internship.  You have been selected as a member 
of a small survey sample and your individual response is crucial for the success of this 
study.   The survey should take approximately 5 to 10 minutes to complete and consists of 
10 questions.  This study has been approved by the University of New Mexico Institutional 
Review Board.  By completing this survey you are indicating your consent to participate in 
this study. 
 
Please click on the following link to access the survey: 
http://www.surveymonkey.com/s/3JSZH75. The survey is titled: “Practices of Registered 
Dietitians in New Mexico Regarding Enteral Nutrition in Patients with Crohn’s disease”.   
 
If you have completed this survey, thank you very much for your assistance.   
 
Thank you for your participation and support, 
 
Nicole Horvath  
Graduate Student & Dietetic Intern 
University of New Mexico 
(505)610-4623 
nhorvath@unm.edu 
 
  
 
48 
 
APPENDIX G: STUDY QUESTIONNAIRE 
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APPENDIX H: APPROVED CONSENT COVER LETTER 
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APPENDIX I: REGISTERED DIETITIANS’ ADDITIONAL COMMENTS 
 
Additional Comments Reported by RDs that Work with Patients with Active CD: 
 “I have had only 2 patients with active Crohn’s Disease, both of which initially 
required TPN r/t small bowel resections.  The only reason these patients were 
transitioned to EN as opposed to oral feedings was because both were too weak to 
pass a swallow evaluation.  And both tolerated the EN without problems.  Both 
had good outcomes.” [This RD reported that she used semi-elemental 
formulations for these patients].  
 “I agree with the use of EN designed for malabsorptive conditions in severe 
Crohn’s [disease].  We do not see a lot of patients, but do have them on 
occasion.”  
 “I will prescribe a low residue diet if they [patients] are somewhat symptomatic.” 
 “Diet may not be as important as we once thought.” 
 “RD clinicians need simple, bullet-pointed guidelines on best practices on use of 
enteral [nutrition] to give to physicians.  Need to keep them educated with quick 
info.” 
 “Will use it [EN] only if not tolerating oral intake.” 
 “I work at a level 3 trauma center for last 11 years and though we seen plenty of 
Crohn’s disease [patients] we don’t see them for that only and most of the time 
they do not need nutrition support.  I have had one [who received nutrition 
support] in the last 11 years.  I have an interest in Crohn’s as my good friend was 
diagnosed when we were 26.  I have learned a lot from her journey and this is 
why I remember this odd fact.  Thanks for the study.” 
 “I would love to know more...I’ve only had one patient so far.  I’d love some 
nutrition assessment & diagnosis guidelines, support guidelines, and MNT 
guidelines.” [This respondent reported in a previous question that she was using 
TPN for her one patient with CD]. 
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